Exact Sciences: Downtrend May Be BrokenExact Sciences jumped on strong earnings two weeks ago, and some traders may think the oncology stock has further upside.
The first pattern on today’s chart is the bullish price gap on May 2 after results beat estimates. Prices apparently broke a falling trendline in the process.
EXAS then consoli
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.869 CHF
−934.41 M CHF
2.51 B CHF
185.81 M
About Exact Sciences Corporation
Sector
Industry
CEO
Kevin T. Conroy
Website
Headquarters
Madison
Founded
1995
FIGI
BBG00LVDBGJ2
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Rotation to healthcare ?Analysis of NLBNPIT1YHG3 certificate: EXACT SCIENCES, VRTX, AGILENT TECHNOLOGIES
Article debut: 18 March 2025
The certificate is at justcertificate.com
As a general rule, "buy the rumors and sell the news" works in most cases, so we won't deny it, but reports of rotations to industries like healt
EXAS a Bullish OutlookAs I predicted before, I had a 100% success rate. Let's consider a long position based on the current technical indicators.
Trend Line: We have a yellow trend line where the price bounced in 2016 and 2022. We are now approaching this trend line again.
Bat Pattern: The bat pattern indicates that poi
Exact Sciences: Anticipating a Market Correction Amidst OverbougExact Sciences is exhibiting bullish tendencies at present, but it's critical to anticipate a substantial correction upon touching, or descending below, the 0.618 Fibonacci retracement level. The stock is likely to retreat to around $70, a significant support level we've observed. The patterns in pl
Exact Sciences (EXAS) - Continuation of the DowntrendBased on my previous technical analysis where Exact Sciences exhibited bullish tendencies but warned of a possible substantial correction around the $70 level, we now find ourselves at a critical junction. Two possible scenarios could unfold from here: a bearish three drives pattern leading to a bou
ABC Correction looks to be over for EXASCorrection could now be over @ 62% retrace.
Looking for a move up to the upper trend line into 2027 based on previous cycles.
+ Momentum divergence at the c wave low suggests energy is building for the next move higher.
Trendchanges and its author are not registered financial advisors. Every
EXAS - Amazing symmetry
If you want to know where price is going to be, look for the history. Will this break out of this range and head higher or flush below?
if it can close above 65 this week, I would keep an eye on it above 68. It moves quickly so a news could push this over/under.
Long via commons and optio
Exact sciences corp Exact Sciences is a biotech stock that is overpriced.
It's time to sell
We touched 3 times the resistance line of a rising wedge pattern, impulsive wave pattern, and RSI 71 weekly overbought zone, the Q2 doesn't seem good.
A leg down to 60$ retesting 69$ which is the resistance line of a rising
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
EXAS5793007
Exact Sciences Corporation 1.75% 15-APR-2031Yield to maturity
3.80%
Maturity date
Apr 15, 2031
EXAS4957195
Exact Sciences Corporation 0.375% 01-MAR-2028Yield to maturity
3.69%
Maturity date
Mar 1, 2028
EXAS4806408
Exact Sciences Corporation 0.375% 15-MAR-2027Yield to maturity
2.71%
Maturity date
Mar 15, 2027
EXAS5549793
Exact Sciences Corporation 2.0% 01-MAR-2030Yield to maturity
2.65%
Maturity date
Mar 1, 2030
See all EXK bonds
Curated watchlists where EXK is featured.
Related stocks
Frequently Asked Questions
The current price of EXK is 44.559 CHF — it has increased by 17.36% in the past 24 hours. Watch EXACT SCIENCES COR stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange EXACT SCIENCES COR stocks are traded under the ticker EXK.
EXK stock has risen by 17.36% compared to the previous week, the month change is a 17.36% rise, over the last year EXACT SCIENCES COR has showed a −35.53% decrease.
We've gathered analysts' opinions on EXACT SCIENCES COR future price: according to them, EXK price has a max estimate of 74.87 CHF and a min estimate of 44.92 CHF. Watch EXK chart and read a more detailed EXACT SCIENCES COR stock forecast: see what analysts think of EXACT SCIENCES COR and suggest that you do with its stocks.
EXK stock is 14.79% volatile and has beta coefficient of 0.48. Track EXACT SCIENCES COR stock price on the chart and check out the list of the most volatile stocks — is EXACT SCIENCES COR there?
Today EXACT SCIENCES COR has the market capitalization of 8.93 B, it has increased by 2.46% over the last week.
Yes, you can track EXACT SCIENCES COR financials in yearly and quarterly reports right on TradingView.
EXACT SCIENCES COR is going to release the next earnings report on Aug 5, 2025. Keep track of upcoming events with our Earnings Calendar.
EXK earnings for the last quarter are −0.48 CHF per share, whereas the estimation was −0.33 CHF resulting in a −44.05% surprise. The estimated earnings for the next quarter are −0.10 CHF per share. See more details about EXACT SCIENCES COR earnings.
EXACT SCIENCES COR revenue for the last quarter amounts to 625.68 M CHF, despite the estimated figure of 609.62 M CHF. In the next quarter, revenue is expected to reach 643.22 M CHF.
EXK net income for the last quarter is −89.60 M CHF, while the quarter before that showed −785.22 M CHF of net income which accounts for 88.59% change. Track more EXACT SCIENCES COR financial stats to get the full picture.
No, EXK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 25, 2025, the company has 7 K employees. See our rating of the largest employees — is EXACT SCIENCES COR on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EXACT SCIENCES COR EBITDA is 21.37 M CHF, and current EBITDA margin is 0.84%. See more stats in EXACT SCIENCES COR financial statements.
Like other stocks, EXK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EXACT SCIENCES COR stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EXACT SCIENCES COR technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EXACT SCIENCES COR stock shows the neutral signal. See more of EXACT SCIENCES COR technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.